KanawatTH
Fresenius Medical Care (NYSE:FMS) fell ~6% Monday afternoon after UBS downgraded the dialysis and related services provider on high consensus earnings estimates.
The agency downgraded the company to Sell from Neutral, and reduced the price target to €42.
The agency believes that the near-term expectations are too high, with the management needing to raise FY23 EBIT guidance by 5% to meet the current consensus.
The agency sees the FRE deconsolidation, GLP-1 data in chronic kidney disease and reimbursement uncertainty driven by the U.S. Supreme Court ruling are “underappreciated exogenous risks”.
The sell-side analysts give the stock a Hold rating, with an average price target of $25.60.
Seeking Alpha analysts and the Quant Rating system give the stock a Buy rating.
